Oliva A, Cogliati Dezza F, Cancelli F, Curtolo A, Falletta A, Volpicelli L
J Clin Med. 2023; 12(24).
PMID: 38137762
PMC: 10743892.
DOI: 10.3390/jcm12247693.
Lennard P, Hiemstra P, Nibbering P
Antibiotics (Basel). 2023; 12(10).
PMID: 37887219
PMC: 10604037.
DOI: 10.3390/antibiotics12101518.
Adema J, Ahiskali A, Fida M, Mediwala Hornback K, Stevens R, Rivera C
Pathogens. 2023; 12(5).
PMID: 37242373
PMC: 10223386.
DOI: 10.3390/pathogens12050703.
Herrera-Hidalgo L, Fernandez-Rubio B, Luque-Marquez R, Lopez-Cortes L, Gil-Navarro M, de Alarcon A
Antibiotics (Basel). 2023; 12(4).
PMID: 37107066
PMC: 10135260.
DOI: 10.3390/antibiotics12040704.
Ledger E, Edwards A
mBio. 2023; 14(1):e0355822.
PMID: 36722949
PMC: 9973334.
DOI: 10.1128/mbio.03558-22.
Bacterial cell membranes and their role in daptomycin resistance: A review.
Nguyen A, Hood K, Mileykovskaya E, Miller W, Tran T
Front Mol Biosci. 2022; 9:1035574.
PMID: 36452455
PMC: 9702088.
DOI: 10.3389/fmolb.2022.1035574.
Breakthrough daptomycin-, linezolid-, vancomycin-resistant bacteremia during protracted daptomycin therapy: A case report.
Pincus N, Joshi T, Gatesy S, Al-Heeti O, Moore W, Bachta K
IDCases. 2022; 29:e01593.
PMID: 35966277
PMC: 9372734.
DOI: 10.1016/j.idcr.2022.e01593.
Evolution of Enterococcus faecium in Response to a Combination of Daptomycin and Fosfomycin Reveals Distinct and Diverse Adaptive Strategies.
Supandy A, Mehta H, Tran T, Miller W, Zhang R, Xu L
Antimicrob Agents Chemother. 2022; 66(6):e0233321.
PMID: 35543524
PMC: 9211409.
DOI: 10.1128/aac.02333-21.
A clinical and assessment of outpatient parenteral benzylpenicillin and ceftriaxone combination therapy for enterococcal endovascular infections.
Ingram P, Ng J, Mathieson C, Mowlaboccus S, Coombs G, Raby E
JAC Antimicrob Resist. 2021; 3(3):dlab128.
PMID: 34377984
PMC: 8346702.
DOI: 10.1093/jacamr/dlab128.
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent.
Ridyard K, Overhage J
Antibiotics (Basel). 2021; 10(6).
PMID: 34072318
PMC: 8227053.
DOI: 10.3390/antibiotics10060650.
Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Biofilm Model.
Jahanbakhsh S, Singh N, Yim J, Kebriaei R, Smith J, Lev K
Antimicrob Agents Chemother. 2020; 64(5).
PMID: 32094136
PMC: 7179592.
DOI: 10.1128/AAC.02074-19.
Emergence of High-level Gentamicin Resistance among Clinical Isolates from Burn Patients in South-west of Iran: Vancomycin Still Working.
Labibzadeh M, Abbas Kaydani G, Savari M, Ekrami A
Pol J Microbiol. 2018; 67(4):401-406.
PMID: 30550226
PMC: 7256818.
DOI: 10.21307/pjm-2018-043.
Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions.
Kebriaei R, Rice S, Singh K, Stamper K, Dinh A, Rios R
Antimicrob Agents Chemother. 2018; 62(8).
PMID: 29760141
PMC: 6105850.
DOI: 10.1128/AAC.00315-18.
A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.
Beganovic M, Luther M, Rice L, Arias C, Rybak M, LaPlante K
Clin Infect Dis. 2018; 67(2):303-309.
PMID: 29390132
PMC: 6248357.
DOI: 10.1093/cid/ciy064.
A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.
Chuang Y, Chen P, Lin C, Chen Y, Wang J, Chang S
Sci Rep. 2018; 8(1):1632.
PMID: 29374204
PMC: 5786011.
DOI: 10.1038/s41598-018-19986-8.
Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.
Benamu E, Deresinski S
F1000Res. 2018; 7:3.
PMID: 29333263
PMC: 5750719.
DOI: 10.12688/f1000research.11831.1.
Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.
Werth B, Shireman L
Antimicrob Agents Chemother. 2017; 61(4).
PMID: 28096164
PMC: 5365715.
DOI: 10.1128/AAC.02235-16.
Molecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.
Renzoni A, Kelley W, Rosato R, Martinez M, Roch M, Fatouraei M
Antimicrob Agents Chemother. 2016; 61(1).
PMID: 27795377
PMC: 5192149.
DOI: 10.1128/AAC.01634-16.
Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.
Hall Snyder A, Werth B, Nonejuie P, McRoberts J, Pogliano J, Sakoulas G
Antimicrob Agents Chemother. 2016; 60(10):5716-23.
PMID: 27431211
PMC: 5038233.
DOI: 10.1128/AAC.00687-16.
Emergence of a daptomycin-non-susceptible Enterococcus faecium strain that encodes mutations in DNA repair genes after high-dose daptomycin therapy.
Matono T, Hayakawa K, Hirai R, Tanimura A, Yamamoto K, Fujiya Y
BMC Res Notes. 2016; 9:197.
PMID: 27036708
PMC: 4818489.
DOI: 10.1186/s13104-016-2003-9.
